A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
Status:
Recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
The main goal of the study is to assess the long-term safety of eptinezumab on children and
adolescents ages 6 to 17 with chronic or episodic migraine.